Editas Medicine (EDIT) Income from Non-Controlling Interests (2022 - 2025)
Editas Medicine (EDIT) posted quarterly Income from Non-Controlling Interests of -$73000.0 for Q2 2025, up 37.07% year-over-year from -$53257.9 in Q2 2024, and up 59.44% quarter-over-quarter from -$180000.0 in Q1 2025.
Editas Medicine (EDIT) Income from Non-Controlling Interests (2022 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Income from Non-Controlling Interests for 4 consecutive years, with -$73000.0 the latest figure, recorded in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | -180,000.00 |
| Jun 30, 2024 | -116,000.00 |
| Mar 31, 2024 | -524,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | 1.32 Mn |
| Jun 30, 2022 | -878,000.00 |
| Mar 31, 2022 | -2.02 Mn |